Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
QD3hQXHQZSskjQyB